Increasing cases of Inflammatory Bowel Disease (IBD) in various regions lead to increased demand for advanced diagnostic and treatment in the Inflammatory Bowel Disease market, which in turn contribute to the growth of the market. Also, there are different factors contributing to higher diagnosis rates such as higher disease burden of IBD, major advances both in understanding disease pathogenesis and the developing newer diagnostic and therapeutic agents. In addition to the above-increasing awareness among physicians and better diagnostic modalities picking up UC early in the disease course and improvement in access to healthcare systems, more widely available diagnostic tools, and increased awareness on the part of both patients and physicians.
Key players such as Gilead Sciences, AbbVie, Arena Pharmaceuticals, Eli Lilly, and others are also investigating their candidates for IBD. The Inflammatory Bowel Disease market is anticipated to grow due to some other factors as well such as increase in the patient pool, expected entry of emerging therapies, and others.
LAS VEGAS, April 11, 2022 /PRNewswire/ -- DelveInsight's Inflammatory Bowel Disease Market Insights report proffers a detailed comprehension of Inflammatory Bowel Disease market size by treatment, epidemiology, emerging therapies, market share of the individual therapies, current and forecasted Inflammatory Bowel Disease market size from 2018 to 2033 segmented into APAC region.
Some of the essential features of the Inflammatory Bowel Disease Market Report:
- The Inflammatory Bowel Disease (IBD) market size in the APAC Region was estimated at around USD 1.46 billion in 2018 and is expected to grow at a CAGR of 8% for the study period (2018-2030).
- Major pharmaceutical Inflammatory Bowel Disease companies such as Takeda Pharmaceutical, Janssen Pharmaceuticals, Hoffmann-La Roche, Genentech, AbbVie, Boehringer Ingelheim, Gilead Sciences, Arena Pharmaceuticals, Eli Lilly, AstraZeneca, Kissei Pharmaceutical, E A Pharma, Galapagos NV, Celgene (Bristol-Myers Squibb), RedHill Biopharma, Pfizer, and others are reported to bring a significant shift in the Inflammatory Bowel Disease market
- The Inflammatory Bowel Disease emerging therapies that are expected to launch in the forecast period include Etrolizumab (RG7413), Risankizumab (ABBV-066), Rinvoq, Etrasimod (APD334), Mirikizumab (LY3074828), Brazikumab, AJM300, Filgotinib, Zeposia (Ozanimod; RPC1063), Tremfya (Guselkumab), RHB-104, Xeljanz and others.
- Of the Inflammatory Bowel Disease emerging therapies Skyrizi, Etrolizumab, Jyselica, and others are expected to enter the treatment market, during the forecast period. Alofisel is recently approved in Japan in 2021.
- The IBD market size in the APAC region is expected to reach USD 3,672 million by 2030. In 2021, China accounted for the highest market size of IBD, compared to the other major markets, i.e., USD 748 million. Among the other APAC countries apart from China, Japan had the highest market size with USD 709 million in 2021, while South Korea had the lowest market size of IBD with USD 75 million in 2021.
For further information on market impact by therapies, download Inflammatory Bowel Disease market sample at Inflammatory Bowel Disease Therapeutic Scenario
Inflammatory Bowel Disease Overview
Like any other part of the body, the digestive system and its organs are affected by different ailments, Inflammatory Bowel Disease (IBD) being one of them. Inflammatory Bowel Disease (IBD) is an umbrella term used to describe disorders that involve chronic inflammation of any part of the digestive tract.
The inflammation in the digestive tract affects its normal functioning and hampers the nutrient uptake by the body. It is a chronic condition, which means it lasts a long time or constantly comes and goes. There are two types of Inflammatory Bowel Disease: Crohn's disease (CD) and Ulcerative colitis (UC).
Inflammatory Bowel Disease Epidemiology Segmentation
Total prevalence of IBD in the APAC regions was 3,907,112 cases in 2021 which is expected to increase during the study period.
Japan accounted for third highest (205,859) cases of IBD, compared to other Asian regions (China (1,917,172 cases), India (1,566,102 cases), Australia (168,539 cases), and South Korea (49,440 cases)) in 2021.
Males accounted for the higher number of IBD cases in the APAC region in 2021. There were 1,708,495 cases and 1,293,034 cases of IBD in males and females respectively in 2021.
The Inflammatory Bowel Disease Market report proffers epidemiological analysis for the study period 201_-3_ in the APAC Region segmented into
- Number of Prevalent Cases of Inflammatory Bowel Disease (IBD)
- Number of Diagnosed Prevalent Cases of IBD
- Gender-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD)
- Type-specific Diagnosed Prevalent Cases of IBD
- Severity-specific Diagnosed Prevalent Cases of Inflammatory Bowel Disease (IBD)
- Age-specific Diagnosed Prevalent Cases of IBD
Keen to learn how Inflammatory Bowel Disease Epidemiological Trends are going to appear in 2030 for the 7 MM, Download at Inflammatory Bowel Disease Epidemiological Insights
Inflammatory Bowel Disease Market Outlook
Inflammatory Bowel Disease is a disease that has no cure. Inflammatory Bowel Disease treatment aims to relieve symptoms, prevent other problems and future flare-ups, and possibly heal the inflamed intestines. Different Inflammatory Bowel Disease treatment approaches are followed for treating a patient. IBD Treatment involves medications as well as surgery and lifestyle changes.
Inflammatory Bowel Disease treatment aims to stop the abnormal inflammation, so intestinal tissue has a chance to heal. As it does, the symptoms of diarrhea and abdominal pain should be relieved. Once the symptoms are under control, medical treatment focuses on decreasing the frequency of flare-ups and maintaining remission. Doctors often take a step-by-step approach to use medications for inflammatory bowel disease. This way, the least harmful drugs or drugs that are only taken for a short period of time are used first. If they do not work, drugs from a higher step are used.
Some of the Inflammatory Bowel Disease marketed drugs include Entyvio (Vedolizumab) which is a gut-selective biologic developed by Takeda Pharmaceutical and Stelara (Ustekinumab) developed by Janssen Pharmaceuticals which is a prescription medicine approved for the treatment of adults 18 years and older with moderately to severely active Crohn's disease and Ulcerative Colitis.
In addition to that, among the Inflammatory Bowel Disease emerging drugs are Etrolizumab (RG7413), which Roche and Genentech are developing, is a humanized IgG1 MAb targeting the beta-7 integrin subunit. The landmark study program includes more than 3,100 patients across six Phase III studies, Risankizumab (ABBV-066) which is an anti-IL-23 antibody being investigated by AbbVie and Boehringer Ingelheim. It is investigated to treat multiple inflammatory diseases, including Crohn's disease and Ulcerative Colitis. Of the emerging therapies Skyrizi, Etrolizumab, Jyselica, and others are expected to enter the treatment market, during the forecast period.
Discover more about therapy set to grab substantial Inflammatory Bowel Disease market share at Inflammatory Bowel Disease Market Landscape
Inflammatory Bowel Disease Pipeline Therapies and Key Companies
- Etrolizumab (RG7413): Hoffmann-La Roche, Genentech
- Risankizumab (ABBV-066): Hoffmann-La Roche, Genentech
- Rinvoq: AbbVie
- Etrasimod (APD334): Arena Pharmaceuticals
- Mirikizumab (LY3074828): Eli Lilly
- Brazikumab: AstraZeneca
- AJM300: Kissei Pharmaceutical, E A Pharma
- Filgotinib: Gilead Sciences, Galapagos NV
- Zeposia (Ozanimod; RPC1063): Celgene (Bristol-Myers Squibb)
- Tremfya (Guselkumab): Janssen Pharmaceuticals
- RHB-104: RedHill Biopharma
To know about more pipeline therapies covered in the report, visit at Inflammatory Bowel Disease Pipeline Analysis, Clinical Trials, and Emerging Therapies
Inflammatory Bowel Disease Market Dynamics
Market Drivers for Inflammatory Bowel Disease:
- Involvement of digital technology for new-age Inflammatory Bowel Disease treatment
- Rich emerging pipeline of Inflammatory Bowel Disease therapeutic area
- Ample opportunity for new molecules with novel mechanisms of action
- Potential for the development of more targeted therapeutics
- Increasing prevalence of Crohn's disease and Ulcerative Colitis globally
- New biomarkers for Inflammatory Bowel Disease diagnosis
- Rise in awareness regarding IBD
Market Barriers for Inflammatory Bowel Disease:
- Entry of biosimilars in the Inflammatory Bowel Disease market
- Insufficient knowledge of the disease
- Significant drawbacks of currently existing therapeutic options in IBD treatment
Know which therapy is expected to score the touchdown first at Inflammatory Bowel Disease Market Landscape and Forecast
Scope of the Inflammatory Bowel Disease Market Report
- Study Period: 2018-30
- Coverage: APAC Region
- Key IBD Companies: Takeda Pharmaceutical, Janssen Pharmaceuticals, Hoffmann-La Roche, Genentech, AbbVie, Boehringer Ingelheim, Gilead Sciences, Arena Pharmaceuticals, Eli Lilly, AstraZeneca, Kissei Pharmaceutical, E A Pharma, Galapagos NV, Celgene (Bristol-Myers Squibb), RedHill Biopharma
- Key Inflammatory Bowel Disease Pipeline Therapies: Etrolizumab (RG7413), Risankizumab (ABBV-066), Rinvoq, Etrasimod (APD334), Mirikizumab (LY3074828), Brazikumab, AJM300, Filgotinib, Zeposia (Ozanimod; RPC1063), Tremfya (Guselkumab), RHB-104
- Inflammatory Bowel Disease Therapeutic Assessment: Inflammatory Bowel Disease current marketed and emerging therapies
- Inflammatory Bowel Disease Market Dynamics: Inflammatory Bowel Disease market drivers and barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
- Unmet Needs
- KOL views
- Analyst's views
- Inflammatory Bowel Disease Market Access and Reimbursement
Request for a Webex demo of the report at Inflammatory Bowel Disease Therapeutics Market
Table of Contents
1 | Key Insights |
2 | Report Introduction |
3 | Inflammatory Bowel Disease Market Overview at a Glance |
4 | Executive Summary of Inflammatory Bowel Disease |
5 | Inflammatory Bowel Disease Epidemiology and Market Methodology |
6 | Inflammatory Bowel Disease: Disease Background and Overview |
7 | Diagnosis of Inflammatory Bowel Disease |
8 | Inflammatory Bowel Disease Treatment |
9 | Conclusion for Inflammatory Bowel Disease |
10 | Inflammatory Bowel Disease Epidemiology and Patient Population |
11 | Inflammatory Bowel Disease Patient Journey |
12 | Key Endpoints in Inflammatory Bowel Disease Clinical Trials |
13 | Inflammatory Bowel Disease Marketed Therapies |
14 | Inflammatory Bowel Disease Emerging Therapies |
15 | Inflammatory Bowel Disease: 7 Major Market Analysis |
16 | Market Access and Reimbursement |
17 | KOL Views |
18 | Inflammatory Bowel Disease Market Drivers |
19 | Inflammatory Bowel Disease Market Barriers |
20 | Inflammatory Bowel Disease SWOT Analysis |
21 | Inflammatory Bowel Disease Unmet Needs |
22 | Appendix |
23 | DelveInsight Capabilities |
24 | Disclaimer |
25 | About DelveInsight |
Get in touch with our Business executive at Inflammatory Bowel Disease Market Analysis
Related Reports
Ulcerative Colitis Pipeline
DelveInsight's, "Ulcerative Colitis (UC)- Pipeline Insight, 2021," report provides comprehensive insights about 110+ companies and 110+ pipeline drugs in Ulcerative Colitis (UC) pipeline landscape which includes companies like AbbVie, Celgene, Eli Lilly and Company, Lipid Therapeutics, Hoffmann-La Roche, Arena Pharmaceuticals, Theravance Biopharma, Boehringer Ingelheim, Janssen Research & Development, PurGenesis Technologies, Protagonist Therapeutics, Pfizer, and several others.
Irritable Bowel Syndrome Pipeline
DelveInsight's, "Irritable Bowel Syndrome (IBS) - Pipeline Insight, 2021," report provides comprehensive insights about 24+ companies and 24+ pipeline drugs in the Irritable Bowel Syndrome (IBS) pipeline landscape including key companies like Boston Pharmaceuticals, RedHill Biopharma Limited, Takeda, Cosmo Technologies, CinRx Pharma, Rottapharm, SK biopharmaceuticals, Synthetic Biologics, Biomica, and various others.
Crohn's Disease Pipeline
DelveInsight's, "Crohn's Disease - Pipeline Insight, 2021," report provides comprehensive insights about 90+ companies and 90+ pipeline drugs in Crohn's Disease pipeline landscape, which includes key companies like Amgen, Pfizer, Hoffmann-La Roche, Gilead Sciences, Eli Lilly and Company, Celgene, AstraZeneca, Abbvie, Mesoblast, and many others.
Chronic Pancreatitis Market
DelveInsight's 'Chronic pancreatitis (CP) - Market Insights, Epidemiology and Market Forecast-2030' report delivers an in-depth understanding of the disease, current treatment practice/algorithm, market drivers, market barriers, unmet needs, and key companies involved like Aptalis Pharma, Digestive Care Inc, Kangen Pharmaceuticals, AzurRx BioPharma, and several others.
Ascites Market
DelveInsight's 'Ascites-Market Insights, Epidemiology, and Market Forecast-2030' report deliver an in-depth understanding of the Ascites, current treatment practice/algorithm, market drivers, market barriers, unmet needs, and key companies involved like BioVie, Noorik Biopharmaceuticals AG, and others.
Eosinophilic Esophagitis Market
DelveInsight's 'Eosinophilic Esophagitis (EoE)- Market Insights, Epidemiology, and Market Forecast-2030' report delivers an in-depth understanding of the disease, current treatment practice/algorithm, market drivers, market barriers, unmet needs, and key companies involved like Dr Falk Pharma GmbH, Takeda, Regeneron Pharmaceuticals/Sanofi, Bristol-Myers Squibb, Ellodi Pharmaceuticals, AstraZeneca, Allakos, EsoCap AG, Arena Pharmaceutical, GlaxoSmithKline and others.
Chronic Venous Ulceration Market
DelveInsight's 'Chronic Venous Ulceration (CVU) - Market Insights, Epidemiology and Market Forecast- 2030' report delivers an in-depth understanding of the CVU, historical and forecasted epidemiology, market drivers, market barriers, and key companies involved like Merck, Bristol-Myers Squibb, Eli Lilly, Taiho Oncology, Hutchison Medipharma Ltd, G1 Therapeutics, Isofol Medical, AB Science, Seagen, Effector Therapeutics, and many more.
Ulcerative Proctitis Pipeline
DelveInsight's, "Ulcerative Proctitis - Pipeline Insight, 2021," report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in the Ulcerative Proctitis pipeline landscape, which includes companies like First Wave Bio, Dr Falk Pharma, Alfasigma, Cristcot LLC, and several others.
Browse Through Our Blog Posts
Novel Therapies in Crohn's Disease Therapeutic Market
Kinase Inhibitors: New standard of care in autoimmune diseases?
Autoimmune Diseases Improvement in Treatment by Major Pharmas
About DelveInsight
DelveInsight is a pioneer in stipulating state-of-the-art services to the clients, also serving as a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma Market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com
Connect With Us at LinkedIn | Facebook | Twitter
Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
